Chrysin, but not the flavone backbone, decreases anxiety-like behavior in animal tests

León Jesús German-Ponciano[1, 2], Bruna Patrícia Dutra Costa[3, 4], Leonardo Miranda Feitosa[5], Kimberly dos Santos Campos[5], Suianny Nayara da Silva Chaves[4], Jonathan Cueto-Escobedo[2, 6], Monica Gomes Lima-Maximino[3, 5], Juan Francisco Rodríguez-Landa[1, 2, 7], Caio Maximino[3, 4, *]

1 Programa de Posgrado en Neuroetología, Instituto de Neuroetología, Universidad Veracruzana, Xalapa, Veracruz, México
2 Laboratorio de Neurofarmacología, Instituto de Neuroetología, Universidad Veracruzana, Xalapa, Veracruz, México
3 Rede de Biodiversidade e Biotecnologia da Amazônia Legal, Brasil
4 Laboratório de Neurociências e Comportamento "Frederico Guilherme Graeff", Instituto de Estudos em Saúde e Biológicas, Universidade Federal do Sul e Sudeste do Pará, Marabá, Pará, Brasil
5 Laboratório de Neurofarmacologia e Biofísica, Centro de Ciências Biológicas e da Saúde, Universidade do Estado do Pará, Marabá, Pará, Brasil
6 Instituto de Ciencias de la Salud, Universidad Veracruzana, Xalapa, Veracruz, México
7 Facultad de Quimica Farmaceutica Biologica, Universidad Veracruzana, Xalapa, Veracruz, México

* Caio Maximino Laboratório de Neurociências e Comportamento – Instituto de Estudos em Saúde e Biológicas, Universidade Federal do Sul e Sudeste do Pará, Unidade III Av. dos Ipês, S/N, s/ CEP, Bairro Cidade Jardim, Marabá/PA, Brazil cmaximino@unifesspa.edu.br

Abstract

Chrysin (5,7-dihydroxyflavone), a flavonoid present in diverse plants, has a backbone structure shared with the basic structure of the flavones, with additional hydroxyl groups that confers its antioxidant properties and effects at the GABAA receptor complex. However, whether these effects are due to the hydroxyl groups is unknown. Here we report the effects of chrysin or the flavone backbone (1 mg/kg) on rat behavior in the elevated plus-maze (EPM) and a locomotor activity test (LAT), as well as in the zebrafish light/dark test (LDT). Chrysin, but not flavone, increased entries and time in the open arms of the EPM, as well as time on white in the zebrafish LDT. These effects were comparable to diazepam, and were devoid of motor effects in both tests, as well as in the rat LAT. On the other hand, flavone increased risk assessment in the zebrafish LDT and rat EPM, suggesting effects threat information gathering; important species differences suggest new avenues of research. It is suggested that the specific effects of chrysin in relation to flavone are due to its free radical scavenging abilities and/or its action at the $GABA_A$/benzodiazepine receptor complex.

Introduction

Flavonoids are polyphenolic compounds present in diverse plants (Ghosh and Scheepens, 2009; Krafczyk et al., 2009). The majority of these compounds have been linked with protective effects against oxidative damage (Hwang and Yen, 2008; Wolfe and Liu, 2008), in addition to its pharmacological action on the Central Nervous System (German-Ponciano et al., 2018). Particularly, the flavonoid chrysin (5, 7-dihydroxyflavone) has been one of the most studied by its antioxidant properties (Siddiqui et al., 2018), but currently also due to its neuropharmacological actions produced on specific brain structures implicated in neuropsychiatric disorders (Filho et al., 2016; Bortolotto et al., 2018).

Figure 1. **Chemical structures of flavone and chrysin.**

Chrysin has a backbone structure that consists in two aromatic rings (A and C), and a phenyl B ring, which is attached to the second position of ring C and shares the basic structure of the flavones, with an additional hydroxyl group in the 5 and 7 positions of the A ring (Mani et al., 2017; Figure 1). The potential of chrysin to act as free radical scavenger has been attributed to the presence of these hydroxyl groups (Sathiavelu et al., 2009; Souza et al., 2015), and it has been suggested that this functional group represents the main action site of this flavonoid to produce a great variety of potential therapeutic effects to ameliorate diverse physiological and psychiatric disorders (Sheela and Angusti, 1995). However, no studies have directly compared the effects of identical doses of chrysin and the basic structure of flavones on the potential therapeutic effects reported at preclinical research.

Chrysin exerts anxiolytic-like effects through action on the $GABA_A$ receptors without the associated side effects (i.e. sedation, amnesia, myrelaxation) that have been attributed to other $GABA_A$ modulators (benzodiazepines, ethanol, etc.); these effects have been evaluated in behavioral models using rodents (Wolfman et al., 1994; Salgueiro et al., 1997; Zanoli et al., 2000; Rodríguez-Landa et al., 2019). Although it has been suggested that presence of the hydroxyl groups in the chrysin structure is the responsible for this pharmacological action, this effect has not been compared with the effects produced by basic structure of the flavones in experimental tests of anxiety-like behavior. The basic flavone moiety has an hydrogen bond donor site, lipophilic pockets, and an electron rich site (Marder and Paladini, 2002); this last is thought to be important for the binding of both flavonoids and 1,4-benzodiazepines to the central benzodiazepine (BZD) site at $GABA_A$ receptors (Marder and Paladini, 2002). Since the chrysin hydroxyl groups are located in one region of the flavone basic ring that is important for the steric interactions associated with binding, this flavonoid is expected to bind BZD sites with a higher affinity than flavone. As a result, while chrysin is

expected to produce a more potent anxiolytic-like effect due to both its higher affinity 37
to the BZD site and its free radical scavenging ability, the electron rich site of flavone is 38
expected to produce at least some level of anxiolysis due to the moderate affinity to the 39
BZD site. 40

In addition to mammalian model organisms used to study the anxiolytic-like effects 41
of diverse substances, non-mammalian models has been developed that allow researchers 42
to explore the potential therapeutic effects of drugs in a short time (Norton and 43
Bally-Cuif, 2010). The use of zebrafish in preclinical research in the 44
psychopharmacology field has increased recently. Biobehavioral assays of anxiety, such 45
as the rodent light/dark test (LDT), have been adapted to zebrafish, considering that 46
behavioral phenotypes are similar between rodents and zebrafish (Maximino et al., 47
2010a). Behavioral screens using zebrafish have evaluated the effects of clinically 48
effective anxiolytic drugs, including benzodiazepines (Maximino et al., 2011) and 49
ligands of both the central and peripheral BZD sites (Lima-Maximino et al., 2018), 50
suggesting good pharmacological isomorphism and the ability of such screens to identify 51
potential anxiolytic drugs that can progress in the drug development pipeline. In 52
addition to increasing the toolbox of behavioral screens for psychoactive drugs, zebrafish 53
screens and biobehavioral assays also increase our understanding of the "core" 54
mechanisms of behavioral functions, such as fear and anxiety, that are altered in human 55
patients and shared between humans and rodents (Gerlai, 2014). 56

The aim of the present study was to compare the effects of chrysin and the flavone 57
backbone (the basic structure of the flavone without the hydroxyl radical groups), using 58
the light/dark test (LDT) in zebrafish, as well as the rat elevated plus-maze (EPM) and 59
locomotor activity test. This could contribute to identify if anxiolytic-like effects 60
produced by chrysin are due to the presence of hydroxyl radicals in its basic structure, 61
which could impact in the specific design of novel molecules destined to 62
pharmacotherapy of anxiety. This manuscript is a complete report of all the studies 63
performed to test the effect of chyrsin, flavone, or diazepam on anxiety-like behavior in 64
rats and zebrafish. We report all data exclusions (if any), all manipulations, and all 65
measures in the study. 66

Materials and Methods 67

Animals, housing, and baseline conditions. 68

Rats. 32 adult male Wistar rats (2.5 months old), weighing 200-250 g, were used. 69
Animals were housed in Plexiglas cages (4-5 rats per cage) in the Laboratorio de 70
Neurofarmacología (Universidad Veracruzana, Xalapa, Mexico) under a 12 h/12 h 71
light/dark cycle (lights on at 7:00 AM) at 25ºC ± 1ºC with *ad libitu*m access to food 72
and water. The experimental procedures were performed in accordance with national 73
(*Especificaciones Técnicas para la Producción, Cuidado y Uso de Animales de* 74
Laboratorio NOM-062-ZOO-1999) and international (National Institutes of Health 75
Guide for the Care and Use of Laboratory Animals) ethical recommendations. All 76
efforts were made to minimize animal discomfort during the study. 77

Zebrafish. 48 adult zebrafish of the longfin phenotype were used in the present 78
experiments. Animals were acquired in a local aquarium shop (at Belém, Brazil) and 79
kept in collective tanks at the Laboratório de Neurofarmacologia e Biofísica (UEPA, 80
Marabá, Brazil) for at least 2 weeks before experiments started. Conditions in the 81
maintenance tank were kept stable, as described by Lawrence (2007) and recorded in 82
protocols.io (Maximino et al., 2019). Recommendations in the Brazilian legislation 83
(Conselho Nacional de Controle de Experimentação Animal - CONCEA, 2017) were 84
followed to ensure ethical principles in animal care and throughout experiments. 85

Drugs and treatments. 86

Chrysin (CAS 480-40-0, C80105) and flavone (CAS 525-82-6, F2003) were purchased 87
from Sigma-Aldrich Co (St. Louis MO, USA). Dimethylsulfoxide (DMSO) was acquired 88
from Golden Bell Reactivos (México City, México). Diazepam (CAS 439-14-5; Tocris 89
2805) was purchased from Tocris. Chrysin and flavone were dissolved in 5% 90
dimethylsulfoxide (DMSO) and injected *i.p.* Thirty-two rats were assigned to four 91
independent groups ($n = 8$/group). The vehicle group received 5% dimethylsulfoxide 92
(DMSO) solution (Golden Bell Reactivos, México City, México); a second group (CHR) 93
received 1 mg/kg chrysin; a third group (FLAV) received 1 mg/kg flavone; and a fourth 94
group (DZP) received 2 mg/kg diazepam as a positive control. 95

The dose of chrysin (1 mg/kg/i.p.) used in the present study was selected from 96
previous experiments of dose-response curves in rodent experimental models of anxiety, 97
including the elevated plus-maze (Rodríguez-Landa et al., 2019; German-Ponciano et al., 98
in press) where it was identified that this dose of chrysin possesses anxiolytic-like effects 99
similar to those produced by diazepam. To reduce the number of animals used in the 100
present research (Russell et al 2019), therefore, no dose-response curves were pursued, 101
which is consistent with 3Rs (refine, reduce, replace) of ethical recommendations for 102
preclinical research. To compare the pharmacological effects of chrysin, an equivalent 103
dose of flavone (1 mg/kg/i.p.) was selected. The diazepam dose used (2 mg/kg/i.p.) 104
was administered as the reference anxiolytic drug which reduces the anxiety-like 105
behavior in the EPM in Wistar rats (Rodríguez-Landa et al., 2019). Sixty minutes after 106
the injection, the rats were evaluated in the elevated plus maze and then in the 107
locomotor activity test. Zebrafish were randomly drawn from the holding tank 108
immediately before injection and assigned to four independent groups ($n = 12$/group). 109
Groups were identical to those used for rats. The injection volume was 1 μL/0.1 g b.w. 110
(Kinkel et al., 2010). The order with which groups were tested was randomized via 111
generation of random numbers using the randomization tool in 112
`http://www.randomization.com/`. Experimenters were blinded to treatment by using 113

coded vials for drugs. The data analyst was blinded to phenotype by using coding to   114
reflect treatments in the resulting datasets; after analysis, data was unblinded.   115

Apparatuses and methods.   116

Rat elevated plus-maze   The rats were separately evaluated in the elevated plus   117
maze, and then in the locomotor activity test. On the testing day, the rats were brought   118
to the experimental room at 11:00 AM and left for 1 h to acclimate to the novel   119
surroundings. The behavioral tests began at 12:00 AM. The apparatus consisted of two   120
opposite open and closed arms set in a 'plus' configuration, and it was situated in an   121
illuminated room at 40 lux. The open arms were 50 cm length x 10 cm width, and the   122
closed arms were 50 cm length x 10 cm width, with 40 cm-high walls. The entire maze   123
was elevated 50 cm above the floor (Figure 2A). To evaluate the effects of the   124
treatments, the rats were individually placed in the center of the maze, facing an open   125
arm. The following variables were scored: 126

1. *Number of entries into the open arms* (N);   127

2. *Number of entries into the closed arms* (N);   128

3. *Total number of entries* (open arms + closed arms, N);   129

4. *Percentage of open arm entries* (Proportion of entries made in the open arms in   130
   relation to the total number of entries)   131

5. *Time spent on the open arms* (s);   132

6. *Time spent in head-dipping* (s);   133

7. *Number of head-dipping events* (N);   134

8. *Time spent in stretched-attend posture (SAP)* (s);   135

9. *Number of SAP events* (N);   136

After the elevated plus maze test, the rats underwent the locomotor activity test.   137
Approximately 2 min elapsed between tests.   138

Rat locomotor activity test.   Each rat was individually placed in the locomotor   139
activity cage (44 cm length x 33 cm width x 20 cm height; Figure 3A). The floor of the   140
cage was delineated into twelve 11 cm x 11 cm squares to evaluate spontaneous   141
locomotor activity, grooming, and rearing for 5 min. At the beginning of the test, the rat   142
was gently placed in one of the corners of the cage. The following variables were scored: 143

1. *Number of squares crossed* (N); a crossing was considered when the rat passed   144
   from one square to another with its hind legs;   145

2. *Time spent rearing* (s); rearing was considered when the rat emmited a vertical   146
   posture relative to the cage floor   147

3. *Time spent grooming* (s); including paw licking, nose/face grooming, head   148
   washing, body grooming/scratching, leg licking, and tail/genital grooming   149

Digital video cameras (Sony DCR-SR42, 40 optical zoom, Carl Zeiss lens) were installed   150
above each apparatus (elevated plus maze, and locomotor activity test) to record   151
activity. Two independent observers measured the behavioral variables using the ex   152
profeso software to record the number and time (in seconds) of each evaluated   153
behavioral variable until > 95% agreement was reached among the observers. After   154

each test session, the apparatus was carefully cleaned with a 10% ethanol solution to   155
remove the scent of the previous rat, which can influence spontaneous behavior of the   156
subsequent rat.   157

Zebrafish light/dark test.   The light/dark preference (scototaxis) assay was   158
performed as described elsewhere (Maximino et al., 2010b; Maximino, 2018). Briefly, 30   159
min after injection animals were transferred individually to the central compartment of   160
a black/white tank (15 cm height X 10 cm width X 45 cm length; Figure 4A) for a   161
3-min acclimation period, after which, the doors which delimit this compartment were   162
removed and the animal was allowed to freely explore the apparatus for 15 min. While   163
the whole experimental tank was illuminated from above by an homogeneous light   164
source, due to the reflectivity of the apparatus walls and floor average illumination   165
(measured just above the water line) above the black compartment was 225 ± 64.2 166
(mean $\pm$ S.D.) lux, while in the white compartment it was 307 ± 96.7 lux. The   167
following variables were recorded: 168

1. *Time spent on the white compartment* (s), the time spent in the white half of the   169
   tank;   170

2. *Transitions to white* (N), the number of entries in the white compartment made   171
   by the animal throughout the session;   172

3. *Entry duration* (s), the average duration of an entry (time on white / transitions);   173

4. *Erratic swimming* (N), defined as the number of zig-zag, fast, and unpredictable   174
   swimming behavior of short duration;   175

5. *Freezing duration* (s), defined as complete cessation of movements with the   176
   exception of eye and operculum movements;   177

6. *Thigmotaxis* (s), defined as swimming in a distance of 2 cm or less from the white   178
   compartment's walls;   179

7. *Risk assessment* (N), defined as a fast (¡1 s) entry in the white compartment   180
   followed by re-entry in the black compartment, or as a partial entry in the white   181
   compartment (i.e., the pectoral fin does not cross the midline).   182

A digital video camera (Samsung ES68, Carl Zeiss lens) was installed above the   183
apparatus to record the behavioral activity of the zebrafish. Two independent observers,   184
blinded to treatment, manually measured the behavioral variables using X-Plo-Rat 2005   185
(`https://github.com/lanec-unifesspa/x-plo-rat`). Inter-observer reliability was   186
at least > 0.85.   187

Statistical analysis.   188

Data were analyzed using one-way ANOVAs with permutation tests, followed by   189
pairwise permutation tests with p-values adjusted for the false discovery rate. Analyses   190
were made in R (R Core Team, 2018), using the package 'coin' (Hothorn et al., 2006).   191
Outliers were detected using an a priori rule based on median absolute deviation (MAD)   192
of time on white (the main endpoint of the LDT) or time in the open arms (the main   193
endpoint of the EPM), with values above or below 3 MADs being removed (Leys et al.,   194
2013). Using this procedure, one outlier was removed from the flavone-treated group.   195

Open science practices.   196

Hypotheses and methods were not formally pre-registered. Data and analysis scripts can   197
be found at a GitHub repository (`https://github.com/lanec-unifesspa/chrysin`).   198

Results

Rat elevated plus-maze.

In the rat elevated plus-maze (Figure 2A), a main effect of treatment was found for
entries in the open arms (Figure 2B; maxT = 2.4407, p = 0.05), with chrysin (p = 0.024
in relation to control) and diazepam (p = 0.023 in relation to controls) increasing this
variable. No effect was found for entries in the closed arm (Figure 2C; maxT = 1.0295,
p = 0.6392) or total entries (Figure 2D; maxT = 1.5331, p = 0.3679). A significant
effect was found for percentage of entries in the open arms (Figure 2E; maxT = 2.7848,
p = 0.02047), but differences disappeared after adjusting p-values in post-hoc contrasts.
Finally, a significant effect was found for time spent in the open arms (Figure 2F; maxT
= 2.6129, p = 0.03373), with chrysin (p = 0.0257) and diazepam (p = 0.0027)
increasing this variable. No effects were found for time spent head-dipping (Figure 2F;
maxT = 1.3025, p = 0.5123) or number of head-dipping events (Figure 2G; maxT =
0.853, p = 0.8). A significant treatment effect was found for time spent in SAP (Figure
2H; maxT = 2.5326, p = 0.042), but meaningful differences disappeared after adjusting
p-values in post-hoc contrasts. Finally, a significant effect was found for SAP frequency
(Figure 2I; maxT = 3.2229, p = 0.005) with flavone (p = 0.0268 vs CTRL) and
diazepam (p = 0.0168 vs CTRL) reducing SAP.

Figure 2. Effects of chrysin, flavone, and diazepam on the rat elevated plus-maze. A Entries on the open arms. **B** Entries on the closed arms. **C** Entries on all arms. **D** Proportion of entries on the open arms in relation to all entries. **E** Time spent in the open arms. **F** Time spent in head-dipping. **G** Number of head-dipping events. **H** Time spent in stretched-attend posture. **I** Number of stretched-attend posture events. For variables with the same letter, the difference is not statistically significant. Likewise, for variables with a different letter, the difference is statistically significant.

Rat locomotor activity test.

In the rat locomotor activity test (Figure 3A), none of the treatments altered the number of squares crossed in the arena (Figure 3B; maxT = 1.6296, p = 0.3139). Grooming (Figure 3C; maxT = 1.5029, p = 0.3861) was not changed; a significant effect was found for rearing (Figure 3D; maxT = 4.009, p = 0.0002), with the flavone backbone increasing it (p = 0.0089 in relation to controls).

Figure 3. Effects of chrysin, flavone, and diazepam on the rat locomotor activity test. A Scheme of the apparatus and test molecules. **B** Squares crossed. **C** Grooming. **D** Rearing. For variables with the same letter, the difference is not statistically significant. Likewise, for variables with a different letter, the difference is statistically significant.

Zebrafish light/dark test.

In the zebrafish light/dark test (Figure 4A), chrysin (p = 0.0208) and diazepam (p = 0.0208), but not the basic structure of the flavone (p = 0.1487), significantly increased (maxT = 3.7331, p = 0.0007321) the time spent into the white compartment (Figure 4B) in relation to the control group. No significant changes were detected in the duration of entries (maxT = 2.0981, p = 0.1243) or transitions (maxT = 0.67072, p = 0.891) to the white compartment (Figures 4C and 4D, respectively), associated with the treatments.

On the other hand, the basic structure of flavone (p = 0.0201), but not chrysin (p = 0.06649) nor diazepam (p = 0.05843), significantly (maxT= 2.6404, p = 0.03119) reduced risk assessment (Figure 4E) in relation to the control group. Diazepam (p = 0..319), but not chrysin (p = 0.6088) or flavone (p = 0.5098), increased erratic swimming (Figure 4F; maxT = 3.9468, p = 0.002846). No significant changes were observed in thigmotaxis (Figure 4G; maxT = 1.4946, p = 0.3913), or freezing duration (Figure 4H; maxT = 2.3935, p = 0.06058) between treatments.

Figure 4. Effects of chrysin, flavone, and diazepam on the zebrafish light/dark test. A Scheme of the apparatus and test molecules. **B** Time spent on the white compartment. **C** Duration of entries on the white compartment. **D** Entries the white compartment. **E** Frequency of risk assessment events. **F** Frequency of erratic swimming events. **G** Time spent in thigmotaxis. **H** Duration of freezing events. For variables with the same letter, the difference is not statistically significant. Likewise, for variables with a different letter, the difference is statistically significant.

Discussion

The present study demonstrated that 1) the anxiolytic-like effect of flavonoid chrysin in the rat EPM and zebrafish LDT, without locomotor effects, seems to be associated with hydroxyl groups substituted in 5 and 7 positions of the A ring in the basic structure of flavone; and 2) the basic structure of flavone is devoid of anxiolytic-like effects in the rat EPM, but increases risk assessment in the zebrafish LDT and rearing in the rat locomotor activity test. These results contribute to the knowledge that position of hydroxyl groups in the basic structure of flavones is an important structural

characteristic to produces its pharmacological action on the central nervous system, and suggest that a comparative approach is best suited to detect conserved drug effects across species that are more likely to be shared with humans.

In the present experiments, chrysin increased the number of entries into the open arms and in the time spent on the open arms without locomotor effects either in the EPM or in the locomotor activity test, an effect that is consistent with anxiolysis and is comparable to DZP. The effects of chrysin in the EPM have been shown before. Wolfman et al. (1994) showed that chrysin (1 mg/kg) increased the number of entries into the open arms and in the time spent on the open arms, while a higher dose was needed to increase the number of head-dippings in the holeboard. This is in accordance with a recent dose-response curve study where we showed that only the dose of 1 mg/kg (i.p.) chrysin produced an anxiolytic like effect in male Wistar rats in the EPM (German-Ponciano et al., in press). These latter effects has been attributed to the activation of GABAA receptors (Rodríguez-Landa et al., 2019).

Similar effects were observed in the zebrafish LDT, a biobehavioral assay that is based in the preference of zebrafish for dark environments (Serra et al., 1999). This behavior reflects the conflict between a motivation for staying in a "safe" place (i.e. dark compartment) and an innate motivation to explore novel, potentially risky environments (Magno et al., 2015). The zebrafish LDT has been validated pharmacologically as a model to screening diverse anxiolytic drugs (Maximino et al., 2011; Magno et al., 2015). Clinically effective anxiolytic drugs that target different sites of the $GABA_A$ receptor, like diazepam and other benzodiazepines, increase the time spent in the light compartment of the apparatus (Gebauer et al., 2011; Maximino et al., 2011), which has been considered as an anxiolytic-like effect at preclinical-research. Moreover, drugs which indirectly target the central benzodiazepine site at $GABA_A$ receptors - such as FGIN-1-27, a drug that promotes neurosteroidogenesis by activating the translocator protein 18 kDa (TSPO) - have been shown to produce an anxiolytic-like effect in the zebrafish LDT (Lima-Maximino et al., 2018).

In the present study, the flavonoid chrysin increased the time spent in the light compartment in comparison to the control group; however, the basic structure of the flavone did not modify this variable. This variable is the main endpoint of the LDT, and is altered by benzodiazepines and TSPO agonists (Sackerman et al., 2010; Stewart et al., 2010; Maximino et al., 2011; Lima-Maximino et al., 2018). This is concordant with effects observed in the rat EPM. However, chrysin did not alter risk assessment behavior in the present experiments, a variable that has been shown to be sensitive to non-benzodiazepine treatments as well as to benzodiazepines (Maximino et al., 2014; Lima-Maximino et al., 2018). In a multivariate approach, risk assessment has been shown to co-vary with other variables in the LDT, forming a separate cluster from thigmotaxis and time on white (Maximino et al., 2014); thus, risk assessment is sensitive to anxiolytic treatments, but represents a different dimension or factor in the multivariate structure of zebrafish behavior in the LDT.

Surprisingly, the flavone backbone decreased risk assessment in the LDT and SAP in the rat EPM, and increased rearing in the LAT. These outcomes are paradoxical; effects on rearing are difficult to interpret, but it has been suggested (Lever et al., 2006) that rearing is associated with environmental novelty, with a possible cognitive function in information-gathering for escape behavior. However, risk assessment in the LDT and SAP in the EPM can be interpreted as having an information-gathering function as well, suggesting different mechanisms for rearing, on the one hand, and risk assessment behavior in anxiety tests, on the other. Taken together, these results suggest that, although not able to reduce the avoidance of potentially environments such as the open arm of the EPM or the light compartment of the LDT tank, the flavone backbone is able to reduce risk assessment behavior. Risk assessment has been suggested as a

cognitive component of anxiety-like behavior (Blanchard et al., 2011), and is more sensitive than spatiotemporal measures (time spent on open arms) in the EPM to detect effects of serotonergic anxiolytics (Griebel et al., 1997).

It has been reported that the generation of free radicals promote the inactivation of the enzyme glutamate descarboxilase (responsable for the synthesis of GABA), leading to a decrease of GABA concentrations and facilitating excitatory neurotransmission (Singh et al., 2014). Since chrysin, like most flavonoids, exert powerful antioxidant effects, because it possesses highly reactive hydroxyl groups in its basic structure, this confers a potent scavenging free radicals activity (Panche et al., 2016). The aforementioned could promote the GABAergic neurotransmission enhancing, similar to clinically effective benzodiazepine drugs (Harvey, 2015). Moreover, chrysin has been reported to bind to benzodiazepine sites (Medina et al., 1990) and to inhibit aromatase (Campbell and Kurzer, 1993), suggesting that this flavonoid can exert more than one effect in the $GABA_A$/benzodiazepine receptor complex.

Overall the results of the present study show that, in zebrafish and rats, the anxiolytic-like effect of the flavonoid chrysin could be related with the presence of the hydroxyl groups in its basic structure. However, additional work is required to determine the molecular mechanism through the flavonoid chrysin and others flavonoids exert their potential therapeutic to ameliorate anxiety symptoms at preclinical research.

Acknowledgments

This study was partially supported by SEP-CONACyT through funding from Programa de Fortalecimiento Académico del Posgrado de Alta Calidad (C-133/2014) to JFR-L. LJG-P received a fellowship from Consejo Nacional de Ciencia y Tecnología (CONACyT) for postgraduate studies in neuroethology (Reg. 297560) Additionally, he received a research scholarship to Brazil from Dirección General de la Unidad de Estudios de Posgrado de la Universidad Veracruzana. Formatting the preprint for this file was made using a template by Philipp Schlegel (`https://www.overleaf.com/latex/templates/arxiv-slash-biorxiv-template/phncddwqtxpc`).

References

Bortolotto, V. C., Pinheiro, F. C., Araujo, S. M., Poetini, M. R., Bertolazi, B. S., de Paula, M. T., Prigol, M., 2018. Chrysin reverses the depressive-like behavior induced by hypothyroidism in female mice by regulating hippocampal serotonin and dopamine. Eur. J. Pharmacol., 822, 78-84.

Brown, E., Hurd, N. S., McCall, S., Ceremuga, T. E., 2007. Evaluation of the anxiolytic effects of chrysin, a Passiflora incarnata extract, in the laboratory rat. AANA J., 75, 333-337.

Campbell, D. R., Kurzer, M. S., 1993. Flavonoid inhibition of aromatase enzyme activity in human preadipocytes. J. Steroid Biochem. Mol. Biol., 46, 381-388.

Conselho Nacional de Controle de Experimentação Animal - CONCEA, 2017. Diretriz brasileira para o cuidado e a utilização de animais para fins científicos e didáticos - DBCA. Anexo I. Peixes mantidos em instalações de instituições de ensino ou pesquisa científica, Resolução Normativa 30/2016 (2017). Brazil.

Filho, C. B., Jesse, C. R., Donato, F., Del Fabbro, L., de Gomes, M. G., Goes, A. T. R., Roman, S. S., 2016. Neurochemical factors associated with the antidepressant-like effect of flavonoid chrysin in chronically stressed mice. Eur. J. Pharmacol., 791, 284-296.

Gebauer, D. L., Pagnussat, N., Piato, Â. L., Schaefer, I. C., Bonan, C. D., Lara, D. R., 2011. Effects of anxiolytics in zebrafish: similarities and differences between benzodiazepines, buspirone and ethanol. Pharmacol. Biochem. Behav., 99, 480-486.

Gerlai, R., 2014. Fish in behavior research: Unique tools with a great promise! J. Neurosci. Methods, 234, 53-58.

German-Ponciano, L. J., Rosas-Sánchez, G. U., Rivadeneyra-Domínguez, E., Rodríguez-Landa, J. F., 2018. Advances in the preclinical study of some flavonoids as potential antidepressant agents. Scientifica, 2018.

German-Ponciano, L.J., Puga-Olguín, A., Rovirosa-Hernández. M.J., Meza, E., Caba, M., Rodríguez-Landa, J.F. (in press). Differential effects of acute and chronic treatment with the flavonoid chrysin on anxiety-like behavior and Fos immunoreactivity in the lateral septal nucleus in rats. Acta Pharmaceutica, 70.

Ghosh, D., Scheepens A., 2009. Vascular action of polyphenols. Mol. Nutr. Food Res., 53, 322–331.

Harvey, R. C., 2015. Benzodiazepines. In Small Animal Critical Care Medicine (Second Edition) (pp. 864-866).

Hothorn, T., Hornik, K., van de Wiel, M. A., Zeileis, A. (2006). A Lego system for conditional inference. Am. Stat., 60, 257–263.

Hwang, S. L., Yen, G. C., 2008. Neuroprotective effects of the Citrus flavanones against H2O2-induced cytotoxicity in PC12 Cells. J. Agric. Food Chem., 56, 859–864.

Kinkel, M. D., Eames, S. C., Philipson, L. H., Prince, V. E. (2010). Intraperitoneal injection into adult zebrafish. J. Vis. Exp., 42, 2126.

Krafczyk, N., Woyand, F., Glomb, M. A., 2009. Structure-antioxidant relationship of flavonoids from fermented rooibos. Mol. Nutr. Food Res., 53, 635–642.

Lawrence, C., 2007. The husbandry of zebrafish (Danio rerio): A review. Aquaculture, 269, 1-20.

Leys, C., Ley, C., Klein, O., Bernard, P., Licata, L., 2013. Detecting outliers: Do not use standard deviation around the mean, use absolute deviation around the median. J. Exp. Social Psych., 49, 764-766.

Lever, C., Burton, S., O'Keefe, J., 2006. Rearing on hind legs, environmental novelty, and the hippocampal formation. Rev. Neurosci., 17, 111-133.

Lima-Maximino, M. G., Cueto-Escobedo, J., Rodríguez-Landa, J. F., Maximino, C., 2018. FGIN-1-27, an agonist at translocator protein 18 kDa (TSPO), produces anti-anxiety and anti-panic effects in non-mammalian models. Pharmacol. Biochem. Behav., 171, 66-73.

Magno, L. D. P., Fontes, A., Gonçalves, B. M. N., Gouveia Jr, A., 2015. Pharmacological study of the light/dark preference test in zebrafish (Danio rerio): Waterborne administration. Pharmacol. Biochem. Behav., 135, 169-176.

Mani, R., Natesan, V., Arumugam, R., 2017. Neuroprotective effect of chrysin on hyperammonemia mediated neuroinflammatory responses and altered expression of astrocytic protein in the hippocampus. Biomed. Pharmacother., 88, 762-769.

Marder, M., Paladini, A. C., 2002. GABA-A-Receptor ligands of flavonoid structure. Curr. Topics Med. Chem., 2, 853-867.

Maximino, C., 2018. Light/dark preference test for adult zebrafish (Danio rerio). protocols.io. `https://dx.doi.org/10.17504/protocols.io.puydnxw`

Maximino, C., Brito, T. M., da Silva Batista, A. W., Herculano, A. M., Morato, S., Gouveia Jr, A., 2010a. Measuring anxiety in zebrafish: a critical review. Behav. Brain Res., 214, 157-171.

Maximino, C., Brito, T. M., Mattos Dias, C. A. G., Gouveia Jr, A., Morato, S., 2010b. Scototaxis as anxiety-like behavior in fish. Nat. Protoc., 5, 209.

Maximino, C., Lima-Maximino, M. G., Siqueira-Silva, D. H., 2019. Zebrafish (Danio rerio) Environmental Summary, LaNeC (Marabá/PA, Brazil). protocols.io. `https://dx.doi.org/10.17504/protocols.io.rupd6vn`

Maximino, C., Silva, A. W. B., Araújo, J., Lima, M. G., Miranda, V., Puty, B., Benzecry, R., Picanço-Diniz, D. L., Gouveia, A. Jr., Oliveira, K. R., Herculano, A. M., 2014. Fingerprinting of psychoactive drugs in zebrafish anxiety-like behaviors. PLoS one, 9, e103943.

Maximino, C., Silva, A.W.B., Gouveia, J., Herculano, A.M., 2011. Pharmacological analysis of zebrafish (Danio rerio) scototaxis. Prog. Neuropsychopharmacol. Biol. Psychiatry, 35, 624–631.

Medina, J. H., Paladini, A. C., Wolfman, C., de Stein, M. L., Calvo, M., Diaz, L. E., Peña, C., 1990. Chrysin (5,7-di-OH-flavone), a naturally-occurring ligand for benzodiazepine receptors, with anticonvulsant properties. Biochem. Pharmacol., 40, 2227-2231.

National Research Council, 2011. Guide for the care and use of laboratory animals, 8th ed. National Academy Press, Washington DC.

NORMA Oficial Mexicana: Especificaciones técnicas para la producción, cuidado y uso de los animales de laboratorio. NOM-062-ZOO-1999

Norton, W., Bally-Cuif, L., 2010. Adult zebrafish as a model organism for behavioural genetics. BMC Neurosci., 11, 90.

Panche, A. N., Diwan, A. D., Chandra, S. R., 2016. Flavonoids: an overview. J. Nutr. Sci., 5, e47.

Rodríguez-Landa, J. F., Hernández-López, F., Cueto-Escobedo, J., Herrera-Huerta, E. V., Rivadeneyra-Domínguez, E., Bernal-Morales, B., Romero-Avendaño, E., 2019. Chrysin (5,7-dihydroxyflavone) exerts anxiolytic-like effects through GABAA receptors in a surgical menopause model in rats. Biomed. Pharmacother., 109, 2387-2395.

Sackerman, J., Donegan, J. J., Cunningham, C. S., Nguyen, N. N., Lawless, K., Long, A., Benno, R.H., Gould, G. G., 2010. Zebrafish behavior in novel environments: Effects of acute exposure to anxiolytic compounds and choice of Danio rerio line. Int. J. Comp. Psychol. , 23, 43.

Salgueiro, J. B., Ardenghi, P., Dias, M., Ferreira, M. B. C., Izquierdo, I., Medina, J. H., 1997. Anxiolytic natural and synthetic flavonoid ligands of the central benzodiazepine receptor have no effect on memory tasks in rats. Pharmacol. Biochem. Behav., 58, 887-891.

Sathiavelu, J., Senapathy, G. J., Devaraj, R., Namasivayam, N., 2009. Hepatoprotective effect of chrysin on prooxidant-antioxidant status during ethanol-induced toxicity in female albino rats. J. Pharm. Pharmacol., 61, 809-817.

Serra, E. L., Medalha, C. C., Mattioli, R., 1999. Natural preference of zebrafish (Danio rerio) for a dark environment. Braz. J. Med. Biol. Res., 32, 1551-1553.

Sheela, C. G., Angusti, K. T., 1995. Antiperoxide effects of S-allyl cysteine sulphoxide isolated from Allium sativum Linn. and gugulipid in cholesterol diet fed rats. Ind. J. Exp. Biol., 33, 337–341.

Siddiqui, A., Badruddeen, Akhtar, J., Uddin MS, S., Khan, M. I., Khalid, M., Ahmad, M., 2018. A Naturally Occurring Flavone (Chrysin): Chemistry, Occurrence, Pharmacokinetic, Toxicity, Molecular Targets and Medicinal Properties. J. Biol. Act. Prod. from Nat., 8, 208-227.

Singh, P., Singh, D., Goel, R. K., 2014. Phytoflavonoids: Antiepileptics for the future. Channels, 3, 5.

Souza, L. C., Antunes, M. S., Borges Filho, C., Del Fabbro, L., de Gomes, M. G., Goes, A. T. R., Jesse, C. R., 2015. Flavonoid Chrysin prevents age-related cognitive decline via attenuation of oxidative stress and modulation of BDNF levels in aged mouse brain. Pharmacol. Biochem. Behav., 134, 22-30.

Stewart, A., Kadri, F., DiLeo, J., Min Chung, K., Cachat, J., Goodspeed, J., Elegante, M., 2010. The developing utility of zebrafish in modeling neurobehavioral disorders. Int. J. Comp. Psychol., 23, 104-121.

Wolfe, K. L., Liu, R. H., 2008. Structure-activity relationships of flavonoids in the cellular antioxidant activity assay. J. Agric. Food Chem., 56, 8404–8411.

Wolfman, C., Viola, H., Paladini, A., Dajas, F., Medina, J. H., 1994. Possible anxiolytic effects of chrysin, a central benzodiazepine receptor ligand isolated from Passiflora coerulea. Pharmacol. Biochem. Behav., 47, 1-4.

Zanoli, P., Avallone, R., Baraldi, M., 2000. Behavioral characterisation of the flavonoids apigenin and chrysin. Fitoterapia, 71, S117-S123.